Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral formulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tchobaniouk, Lesia V, McAllister, Erin E, Bishop, Danielle L, Carpentier, Rachel M, Heins, Katharine R, Haight, Robert J, Bishop, Jeffrey R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053417/
https://www.ncbi.nlm.nih.gov/pubmed/32184570
http://dx.doi.org/10.2147/PPA.S192418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053417/
https://www.ncbi.nlm.nih.gov/pubmed/32184570
http://dx.doi.org/10.2147/PPA.S192418

Ejemplares similares